1. Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998;113(4 Suppl):235S–41S.
2. National Center for Health Statistics. Health, United States, 2015: with special feature on racial and ethnic health disparities. Hyattsville, MD; 2016.
3. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683–9.
4. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at http://goldcopd.org.
5. Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) – why and what? Clin Respir J 2012;6:208–14.
6. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995;152(5 Pt 2):S77–121.
7. Siafakas N, Vermeire P, Pride Na, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398–420.
8. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–46.
9. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008;63:1046–51.
10. Bestall J, Paul E, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581–6.
11. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347–65.
12. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1256–76.
13. Dirksen A, Christensen H, Evald T, et al. Bronchodilator and corticosteroid reversibility in ambulatory patients with airways obstruction. Danish Med Bull 1991;38:486–9.
14. Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016;48:664–73.
15. Hansen EF, Phanareth K, Laursen LC, et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159(4 Pt 1):1267–71.
16. Ford ES, Croft JB, Mannino DM, et al. COPD surveillance—United States, 1999-2011. Chest 2013;144:284–305.
17. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital and health statistics Ser 1, Programs and collection procedures. 1994:1–407.
18. Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed Obstructive lung disease in the United States. Associated factors and long-term mortality. Ann Am Thorac Soc 2015;12:1788–95.
19. Tilert T, Dillon C, Paulose-Ram R, et al. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res 2013;14:103.
20. Prentice HA, Mannino DM, Caldwell GG, Bush HM. Significant bronchodilator responsiveness and “reversibility” in a population sample. COPD 2010;7:323–30.
21. Chang JT, Moran MB, Cugell DW, Webster JR. COPD in the elderly: a reversible cause of functional impairment. Chest 1995;108:736–40.
22. Ulrik C, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999;14:892–6.
23. Hing E, Hall MJ, Ashman JJ, Xu J. National hospital ambulatory medical care survey: 2007 outpatient department summary. Natl Health Stat Report 2010;28:1–32.
24. Niska R, Bhuiya F, Xu J. National hospital ambulatory medical care survey: 2007 emergency department summary. Natl Health Stat Report 2010;26:1–31.
25. Kozak LJ, DeFrances CJ, Hall MJ. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital and health statistics Series 13, Data from the National Health Survey. 2006(162):1–209.
26. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2013;61:1–117.
27. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997;156(3 Pt 1):814–8.
28. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991;133:795–800.
29. Miller JD, Foster T, Boulanger L, et al. Direct Costs of COPD in the U.S.: An Analysis of Medical Expenditure Panel Survey (MEPS) Data. COPD 2005;2:311–8.
30. Ford ES, Murphy LB, Khavjou O, et al. Total and state-specific medical and absenteeism costs of COPD among adults aged >/= 18 years in the United States for 2010 and projections through 2020. Chest 2015;147:31–45.
31. Mannino DM. Counting costs in COPD: what do the numbers mean? Chest 2015;147:3–5.
32. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197–223.
33. Murray CJ, Abraham J, Ali MK, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591–606.
34. Lopez AD, Murray CC. The global burden of disease 1990–2020. Nat Med 1998;4:1241–3.
35. Cohen SB-Z, Paré PD, Man SFP, Sin DD. The growing burden of chronic obstructive pulmonary disease and lung cancer in women. Am J Respir Crit Care Med 2007;176:113–20.
36. Han MK, Postma D, Mannino DM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med. 2007;176:1179–84.
37. Tanoue LT. Cigarette smoking and women’s respiratory health. Clin Chest Med 2000;21:47–65, viii.
38. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:2152–8.
39. Carter R, Nicotra B, Huber G. Differing effects of airway obstruction on physical work capacity and ventilation in men and women with COPD. Chest 1994;106:1730–9.
40. Foreman MG, Zhang L, Murphy J, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med 2011;184:414–20.
41. Sørheim I-C, Johannessen A, Gulsvik A, et al. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax 2010;65:480–5.
42. Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP, et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994;150:956–61.
43. De Marco R, Locatelli F, Sunyer J, Burney P. Differences in incidence of reported asthma related to age in men and women: a retrospective analysis of the data of the European Respiratory Health Survey. Am J Respir Crit Care Med 2000;162:68–74.
44. Moorman JE, Moorman J, Mannino DM. Increasing US asthma mortality rates: who is really dying? J Asthma 2001;38:65–71.
45. Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma—United States, 1960–1995. MMWR CDC Surveill Summ 1998;47:1–27.
46. Snider GL. Molecular epidemiology: a key to better understanding of chronic obstructive lung disease. Monaldi Arch Chest Dis 1995;50:3–6.
47. Hogg JC. Chronic bronchitis: the role of viruses. Semin Respir Infect 2000;15:32–40.
48. Kraft M, Cassell GH, Henson JE, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 1998;158:998–1001.
49. Hegele RG, Hayashi S, Hogg JC, Paré PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory trad infections. Am J Respir Crit Care Med 1995;151:1659–65.
50. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009;64:6–12.
51. Becklake MR. Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. Am Rev Respi Dis 1989;140(3 Pt 2):S85–S91.
52. Po JYT, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax 2011;66:232–9.
53. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765–73.
54. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003;22:462–9.
55. Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution. Am J Respir Crit Care Med 2011;183:455–61.
56. Agusti À, Soriano JB. COPD as a systemic disease. COPD 2008;5:133–8.
57. Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med 2008;121:789–96.
58. Cekerevac I, Lazic Z, Petrovic M, Novkovic L. COPD and depression. Eur Respir J 2012;40(Suppl 56).
59. Fromer L. Diagnosing and treating COPD: understanding the challenges and finding solutions. Int J Gen Med 2011;4:729–39.
60. Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454–75.
61. Barnes PJ. Gold 2017: A new report. Chest 2017;151:245–6.
62. Choo C. Combination therapy options in Stable COPD. US Pharm 2010;35:31–7.
